Last $8.75 USD
Change Today +0.55 / 6.71%
Volume 31.8K
AGRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

agile therapeutics inc (AGRX) Snapshot

Open
$8.30
Previous Close
$8.20
Day High
$9.09
Day Low
$8.25
52 Week High
06/23/14 - $12.55
52 Week Low
05/23/14 - $5.05
Market Cap
162.7M
Average Volume 10 Days
46.9K
EPS TTM
$-1.14
Shares Outstanding
18.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGILE THERAPEUTICS INC (AGRX)

Related News

No related news articles were found.

agile therapeutics inc (AGRX) Related Businessweek News

No Related Businessweek News Found

agile therapeutics inc (AGRX) Details

Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

11 Employees
Last Reported Date: 08/14/14
Founded in 1997

agile therapeutics inc (AGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $390.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2013.

agile therapeutics inc (AGRX) Key Developments

Agile Therapeutics, Inc. Announces Initiation of its Phase 3 Study

Agile Therapeutics, Inc. announced the initiation of its Phase 3 study called SECURE (Study to Evaluate Contraceptive Use, Reliability and Effectiveness). The SECURE study is designed to assess the efficacy, safety and tolerability of Agile's investigational once-weekly transdermal contraceptive patch, Twirla(TM) (AG200-15). Twirla will be the only low-dose combined hormonal contraceptive patch and delivers the active ingredients ethinyl estradiol and levonorgestrel, both of which have an established history of efficacy and safety in currently marketed combination low-dose oral contraceptives. The SECURE study is a single-arm, open-label, multicenter Phase 3 study of Twirla (AG200-15) that will enroll approximately 2,100 female subjects who will use the patch for up to one year. The study will assess the effectiveness of the patch in preventing pregnancy using the Pearl Index as the primary contraceptive efficacy measure. Safety and tolerability will also be evaluated. The company continues to expect an enrollment period of four to six months. The results from the SECURE study are intended to support the company's new drug application with the U.S. Food and Drug Administration for marketing approval of Twirla (AG200-15) in the United States.

Agile Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Agile Therapeutics, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $3,494,710 against $3,249,070 a year ago. Loss before benefit from income taxes was $3,718,401 against $3,619,879 a year ago. Net loss was $3,718,401 or $0.46 per basic and diluted share against $3,619,879 or $70.29 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $5,942,337 against $7,477,431 a year ago. Loss before benefit from income taxes was $6,531,593 against $8,216,109 a year ago. Net loss was $2,879,108 or $0.71 per basic and diluted share against $8,216,109 or $175.31 per basic and diluted share a year ago.

Agile Therapeutics Approves Restated Certificate of Incorporation

On May 29, 2014, Agile Therapeutics, Inc. filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware in connection with the closing of the Company's initial public offering of shares of its common stock. The company's board of directors and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the company's initial public offering. The Restated Certificate amends and restates in its entirety the company's second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: authorizes 150,000,000 shares of common stock; eliminates all references to the previously existing series of preferred stock; authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the company's stockholders; provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the company entitled to vote generally in the election of directors; provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and requires that any action instituted against the company's officers or directors in connection with their service to the company be brought in the State of Delaware. Effective as of May 29, 2014, the Company adopted amended and restated bylaws in connection with the closing of the Company's initial public offering of shares of its common stock. The Board and the Company's stockholders previously approved the Restated Bylaws effective as of and contingent upon the closing of the Company's initial public offering. The Restated Bylaws amend and restate, in their entirety, the Company's amended and restated bylaws. The Restated Bylaws, among other things: (i) provides that, subject to limited exceptions, vacancies on the Board shall only be filled by the remaining members of the Board; (ii) eliminates the ability of the Company's stockholders to take action by written consent in lieu of a meeting; and (iii) requires advance written notice of stockholder proposals and director nominations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGRX:US $8.75 USD +0.55

AGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGRX.
View Industry Companies
 

Industry Analysis

AGRX

Industry Average

Valuation AGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGILE THERAPEUTICS INC, please visit www.agiletherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.